Key Points
- EVP Ryan Savitz sold 100,713 Dianthus Therapeutics shares for about $9.12 million at an average price of $90.54, reducing his position by 77.48% to 29,276 shares.
- Dianthus reported a quarterly loss of $0.81 per share, beating analyst expectations of a $0.94 loss; revenue of $1.21 million also exceeded estimates of $0.46 million.
- Analysts maintain a consensus Buy rating and an average price target of $128.77. Recent targets range from $113 to $158.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Ryan Savitz sold 17,724 shares of the stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $90.56, for a total transaction of $1,605,085.44. Following the sale, the executive vice president directly owned 29,276 shares in the company, valued at $2,651,234.56. This trade represents a 37.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Ryan Savitz also recently made the following trade(s):
- On Wednesday, November 11th, Ryan Savitz sold 3,044 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.03, for a total transaction of $274,051.32.
- On Monday, November 9th, Ryan Savitz sold 100,713 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.54, for a total transaction of $9,118,555.02.
- On Tuesday, November 10th, Ryan Savitz sold 2,561 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.14, for a total transaction of $230,848.54.
Dianthus Therapeutics Stock Up 3.6%
Shares of DNTH opened at $92.48 on Friday. Dianthus Therapeutics, Inc. has a twelve month low of $34.29 and a twelve month high of $117.88. The company has a market capitalization of $5.21 billion, a P/E ratio of -23.18 and a beta of 1.47. The firm has a 50 day moving average of $88.77 and a 200 day moving average of $86.36.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.13. The business had revenue of $1.21 million for the quarter, compared to analysts' expectations of $0.46 million. Dianthus Therapeutics had a negative return on equity of 19.68% and a negative net margin of 7,436.50%. On average, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -3.55 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. First Trust Advisors LP raised its stake in Dianthus Therapeutics by 42.1% during the 3rd quarter. First Trust Advisors LP now owns 133,810 shares of the company's stock valued at $11,782,000 after buying an additional 39,658 shares during the last quarter. IFG Advisory LLC lifted its holdings in shares of Dianthus Therapeutics by 19.1% during the 3rd quarter. IFG Advisory LLC now owns 6,000 shares of the company's stock valued at $528,000 after buying an additional 961 shares during the period. Fisher Asset Management LLC boosted its stake in shares of Dianthus Therapeutics by 1,068.4% in the 3rd quarter. Fisher Asset Management LLC now owns 272,863 shares of the company's stock worth $24,026,000 after buying an additional 249,510 shares during the last quarter. Fifth Third Bancorp boosted its stake in shares of Dianthus Therapeutics by 23.6% in the 3rd quarter. Fifth Third Bancorp now owns 676 shares of the company's stock worth $60,000 after buying an additional 129 shares during the last quarter. Finally, Keybank National Association OH boosted its stake in shares of Dianthus Therapeutics by 24.1% in the 3rd quarter. Keybank National Association OH now owns 4,355 shares of the company's stock worth $383,000 after buying an additional 845 shares during the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on DNTH. Weiss Ratings restated a "sell (d-)" rating on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Roth Capital began coverage on Dianthus Therapeutics in a report on Tuesday, October 27th. They set a "buy" rating and a $113.00 price target on the stock. Citigroup initiated coverage on Dianthus Therapeutics in a research report on Friday, September 4th. They set a "buy" rating and a $156.00 price objective on the stock. Raymond James Financial reiterated a "strong-buy" rating and issued a $134.00 price objective on shares of Dianthus Therapeutics in a report on Thursday, November 5th. Finally, Truist Financial lifted their price objective on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $128.77.
Get Our Latest Stock Analysis on DNTH
Dianthus Therapeutics Company Profile
(
Get Free Report)
Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company's research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
